Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. AGNPF

Primary Symbol: C.AGN

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RE:RE:AGN.c upcoming milestones

Without an uplist to NASDAQ this stock will most likely remain in the gutter. People want to see data and uplist ro NASDAQ. They have been royally screwed with the 100 to 1 reverse spilit based on more

RE:AGN.c upcoming milestones

With one study in progress and another incoming, AGN is has an established plan for this year and could easily see some catalysts here.   rate and reply

GFI Announces Launch at Sprouts Farmers Market

Global Food and Ingredients Ltd. is pleased to announce its national retail launch into Sprouts Farmers Market in the United States for the Company's Yofiit brand. Sprouts is one of the largest and fastest growing specialty retailers of fresh, natural and organic food in the United States, with roughly 380 stores across 23 states. more
@ the Bell: Markets tumble amid rate worries
Canada’s main stock index was weighed down into the red on Monday by commodity-linked and financial stocks. read article.

Experts Fear Bird Flu Outbreak Could Turn Into New Pandemic

The spread of the avian influenza virus on a mink farm in Spain has some scientists on edge. “This is an infection that has epidemic and pandemic potential,” Dr. Isaac Bogoch, a more
@ the Bell: Growth-sensitive stocks fluctuate on mega jobs report
Canada’s main stock index lost ground in Friday trading as strength in the energy and technology sectors was outweighed by losses among utilities and mining shares. read article.

AGN.c upcoming milestones

Lot of upcoming milestones which could get AGN moving. Look out for data from phase 1 of the DMT study in Q2 of this year along with the beginning of a phase 2b IPF study for chronic cough also more

CEO Interview on Ifenprodil for Chronic Cough

New interview with AGN.c AGNPF CEO (up 5% today). Gives updates on the previously announced 180 patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough that will begin in Q3. more
Buzz on the Bullboards: A meeting that could not have been an email
Stocks closed out the first month of 2023 no worse for wear after getting pummeled last year. A sign of better things on the horizon? Last month, indexes on Bay Street and Wall Street rose, with... read article.

RE:The CEO Wants You To Believe It's Current Market Conditions.

oops!  rate and reply

The CEO Wants You To Believe It's Current Market Conditions.

The CEO claims all your woes are because Penny Stock Investors @ CSE & OTC are stupid people. The CEO has stated the same thing in the recent past then retracted. Says he was misunderstood. more

AGN DMT study and interview

AGN looking to wrap up the DMT phase 1 study some time in June or July. Some solid data from the study in Q2 or Q3 this year could be huge for AGN. Will be on the lookout for more updates here. more

RE:AGN CEO on Radius Research

Insightful interview - there is significant potential here as the phase 2a study showed a significant improvement in patients Ifenprodil is a novel first-in-class potential treatment for more

AGN CEO on Radius Research

Algernon Pharmaceuticals (AGN.c AGNPF) CEO, Christopher Moreau, on Radius Research giving an update on the company's Ifendprodil drug program which aim to test if the drug can help with more

Electratect.  rate and reply

Update: $AGN CEO Chris Moreau - Chronic Cough Drug Program

News Update: Algernon Pharmaceuticals $AGN w CEO Christopher Moreau - Pitch, Deep Dive and Q&A -   CEO Christopher Moreau provides an update on more

AGN CEO on new subsidiary

Algernon Pharmaceuticals (AGN.c AGNPF) CEO on the company's Phase 1 DMT Clinical Stroke Study, why the company decided to create a subsidiary for its DMT research (Algernon Nuro) and plans more

All Roads Lead To Dante's Inferno @ Algernon Pharmaceuticals

Take a look at the performance of Xortx Therapeutics (XRTX) today with its recent move towards a Phase III clinical trial. They're now at 52 week low with no bottom. The relevance is Xortx' more

Algernon NeuroScience, a subsidiary of Algernon Pharmaceutic

Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals, has begun a Phase 1 clinical stroke study of DMT in the Netherlands, using a single-escalating dose design to determine a safe, more


My best guess is over the course of Moreau's management style the big winner in the entire equation is someone whom management (CEO, CSO, CFO) has had a blatant conflict of interest more

A History Of Flip Flop Decisions Remains @ The Helm

@ Radius Research the Interviewer hits the correct number of 150% Dilution with a capital raise of 10M USD. Then turns right around and says a capital raise of 10M USD through Algernon Neuro more

RE:AGN CEO on Radius Research regarding the DMT study update

Thanks for the share, great to hear the positive feedback from psychedelic funds on the study.  rate and reply

AGN CEO on Radius Research regarding the DMT study update

AGN CEO Chris Moreau on Radius Research discussing the more

RE:DMT stroke trial commences with first patient dosed

There is significant potential here as AGN is taking a new approach to stroke treatment that greatly differs from the previous stroke drug treatments that failed. By focusing on more